Dr. Alexander Dimitrios Colevas, MD

Dr. Colevas practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Colevas' NPI, 1588726558, was assigned on December 15, 2006. Dr. Colevas graduated from The Johns Hopkins University School of Medicine in 1989. Dr. Colevas holds California license C52711.

Dr. Colevas' primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Colevas' primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Colevas is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Colevas to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account. Dr. Colevas' employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Colevas practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Colevas' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Colevas is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Colevas' licenses on file in 3 states: California, Maryland and Massachusetts.

Dmand AI lists anemia, breast cancer, lung cancer, lymphoma and prostate cancer among the conditions Dr. Colevas treats.

CMS data shows 1,336 Medicare services from Dr. Colevas across 8 procedure codes in 2024, for 258 Medicare patients. Medicare paid $117,889 for them.

CMS counts 258 Medicare patients who saw Dr. Colevas in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 24% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Colevas' median patient age at 67, with 34% women.

In 2024, Dr. Colevas wrote 374 Medicare Part D claims for 87 patients. 69% of them were for generic drugs. CMS names the drug for 143 of them, across 7 drugs with 11 or more claims each, at $476,296 in total drug cost. In 2023, CMS named 40 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Colevas for performance year 2024, reported as part of a group. Dr. Colevas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Colevas as offering telehealth.

Dmand AI links 146 papers to Dr. Colevas, published from 2006 to 2024. 2019 was the busiest year, with 11. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Antineoplastic Agents. Dr. Colevas has published most often in J Clin Oncol. Dr. Colevas' most frequent co-authors are Marshall R. Posner, MD, Maura L. Gillison, MD and Eben L. Rosenthal, MD.

Dmand AI links Dr. Colevas to 16 clinical trials, 7 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Nasopharyngeal Diseases, Nasopharyngeal Carcinoma and Squamous Cell Carcinoma of Head and Neck. Stanford University sponsors the most, 6.

CMS Open Payments shows 17 general payments to Dr. Colevas from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 43% of the total. Amgen Inc. paid the most, $10,034.

Dmand AI lists 1 award for Dr. Colevas, most recently CMS Stage 1 EHR in 2013.

Dr. Colevas graduated from The Johns Hopkins University School of Medicine in 1989.

Dr. Colevas is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.